Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05616013 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 507
- Enrollment target
NCT05616013: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT05616013 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 507 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (281% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05616013, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 507 participants
- Enrollment target
Study Summary
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
Primary Outcome
Least Square mean was determined by MMRM model for post-baseline measures: Variable is modelled by Gender (Male, Female), Country (Australia, New Zealand, United States of America), Visit, Treatment, and Visit-by-Treatment interaction as fixed effects, and Baseline as a covariate. Variance-Covariance structure= Unstructured. Only participants with non-missing baseline value were included in analysis. No imputation was performed for missing values.
Interventions
- OTHER Placebo
- DRUG Semaglutide
- BIOLOGICAL Bimagrumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2022-11-16 |
| Est. Completion | 2025-06-14 |
| Phase | Phase 2 |
What the finished NCT05616013 record still lists
NCT05616013 is an interventional study that assigns participants to a tested intervention. The registered 507 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (281% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05616013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05616013 about?
NCT05616013 is a clinical study titled "Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese". A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
What is the current status of trial NCT05616013?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 507 participants. The study started on 2022-11-16. Estimated completion is 2025-06-14.
What interventions are being tested in trial NCT05616013?
The interventions under investigation include: Placebo (OTHER), Semaglutide (DRUG), Bimagrumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05616013?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05616013's enrollment target sits among peer trials
507 69th of 2000 higher than 1,932 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- NCT07391657 · 508 participants · Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI